Safety and efficacy of remote ischaemic preconditioning in diabetic kidney disease: a pilot randomised, parallel-arm, sham-controlled trial protocol.

ABSTRACT:

Introduction

Diabetic kidney disease (DKD), characterised by rapid progression and poor prognosis, accounts for approximately 50% of all end-stage renal disease. Remote ischaemic preconditioning (RIP) can reduce the impact of subsequent fatal ischaemic events through brief episodes of ischaemia remote from a target organ. Therefore, we aim to determine whether RIP can slow the renal failure progression in patients with DKD.

Methods and analysis

This is a pilot randomised, parallel-arm, sham-controlled trial of 60 participants with stable DKD (chronic kidney disease stages 3-4). Participants will be randomly assigned to the intervention or control group undergoing one daily RIP or sham RIP for 3 months, with a subsequent 6-month follow-up period. The primary study outcome is

SUBMITTER: Wang L 

PROVIDER: S-EPMC12410602 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature